| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.01 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |